Tags: High Cholesterol | bad cholesterol | LDL cholesterol | evolocumab | PCSK9

New Once-Monthly Drug Cuts Cholesterol

Monday, 17 Mar 2014 12:37 PM


Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting "bad" LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat.
 
Amgen said patients given its injectable drug evolocumab once a month on top of standard daily statin treatments showed "clinically meaningful" improvement compared to statins alone after 12 weeks of treatment.
 
Evolocumab works by blocking PCSK9, a naturally occurring protein that keeps LDL levels elevated in the bloodstream. Other drugmakers, including Pfizer Inc and a partnership between Regeneron Inc and Sanofi, are racing with Amgen to complete trials of potentially lucrative anti-PCSK9 antibodies.
 
ALERT: 4 Things You'll Feel Before a Heart Attack


© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
Health-News
Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting bad LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat. Amgen said patients...
bad cholesterol,LDL cholesterol,evolocumab,PCSK9
124
2014-37-17
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved